Lercanil is primarily used for the long-term, sustained management of essential hypertension, which is a condition marked by persistently elevated blood pressure readings. The medication is commonly used for the treatment of mild to moderate essential hypertension in adults.

This medication addresses the condition by reducing high systemic vascular resistance, thereby contributing to achieving appropriate blood pressure levels over a full 24-hour cycle. It is relevant in conditions marked by increased physiological stress and is often applied when supportive symptom management is appropriate. In addition to initial monotherapy, it is relevant as an agent in combination therapy for patients who are not adequately controlled by a single agent, which supports effective blood pressure management.

Role in Long-Term Cardiovascular Support

Lercanil helps provide crucial long-term support for the cardiovascular system, focusing on reducing the likelihood of serious complications. By maintaining stable blood pressure, it supports the reduction of risk for cardiovascular events associated with hypertension. Furthermore, it may support kidney health in patients with hypertension.

---

Quick Fact: Support for Sustained Blood Pressure Elevation
Main Use: Management of essential hypertension (mild to moderate severity) and support in combination therapy for uncontrolled high blood pressure.
Benefit: Helps maintain a stable blood pressure and helps improve day-to-day comfort during symptomatic periods by reducing long-term cardiovascular stress.

Regulatory References

1. Public Assessment Report Lercanidipine hydrochloride

Eligibility Map: Who can and cannot use Lercanil — official regulatory information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (18 years of age and older) are the approved population.
Populations for whom use is not recommended	Children and adolescents under 18 years. Also pregnancy and lactation status.
Populations for whom use is contraindicated	Patients with severe hepatic impairment or severe renal impairment (GFR <30 mL/min).
Age-related eligibility rules	Adults (18+): Approved for use. Children/Adolescents (Under 18): Use is not established and not recommended.
Condition-specific eligibility rules	Severe Organ Impairment (Hepatic/Renal): Use is contraindicated. Mild to Moderate Organ Impairment: Requires special care when commencing treatment.
Pregnancy and lactation eligibility status	Pregnancy: Not recommended. Lactation: Should not be administered.

---

Resulting Eligibility Structure

Official eligibility statements indicate that Lercanil is strictly reserved for the adult population, as use is not recommended for individuals under 18 years of age. The medicine is contraindicated for populations presenting with specific, severe organ dysfunction, including severe hepatic impairment and severe renal impairment. Further absolute non-eligibility applies to patients with acute cardiac conditions such as untreated congestive heart failure, unstable angina pectoris, or recent myocardial infarction. Use is also prohibited in patients who demonstrate hypersensitivity to any component or who are concurrently using strong CYP3A4 inhibitors or consuming grapefruit/grapefruit juice.

Interactions with other medicines and products

Regulatory documentation defines Lercanil's interaction profile primarily through its metabolism and specific pharmacodynamic outcomes. All interaction statements and restrictions are based on official government drug labels.

Formal Interaction Restrictions

Co-administration is formally contraindicated with strong inhibitors of CYP3A4, including certain antifungals (e.g., Ketoconazole, Itraconazole) and antivirals (e.g., Ritonavir). The label also formally prohibits use with Ciclosporin (Source 1.4, 2.1).

Interaction Type	Affected Products and Outcome
Contraindicated Products	Grapefruit or Grapefruit Juice (Causes a rise in systemic availability and increased hypotensive effect) (Source 1.3, 2.1).
Dietary Restriction	Alcohol (Should be avoided as it may potentiate the vasodilating effect) (Source 1.4, 2.1).
Metabolic Risk	CYP3A4 Inducers (May reduce Lercanil's plasma levels, potentially diminishing efficacy) (Source 1.4, 3.4).
Exposure Alteration	Digoxin (Cmax is documented to increase by 33%); Simvastatin (AUC increased by 56%) (Source 2.1, 3.4).
Timing Requirement	Must be administered at least 15 minutes before a meal (Source 1.1, 3.3).

Co-administration with other antihypertensive agents may result in an increased hypotensive effect. For specific co-medications like Simvastatin, no interaction is expected when Lercanil is taken in the morning and Simvastatin in the evening, as specified in regulatory text (Source 1.4, 3.4).

Molecular Targeting of Vascular Calcium Channels

Lercanil’s mechanism begins with the active ingredient, Lercanidipine, acting as an antagonist of the L-type voltage-gated calcium channels (CaV 1.2) found in the walls of peripheral arterioles. By binding competitively to this channel, Lercanidipine prevents the required transmembrane influx of extracellular calcium ions ( Ca^2+) into the vascular smooth muscle cells. This blockade interrupts the calcium-dependent contractile cascade, resulting in the functional relaxation of the smooth muscle tissue.

Sustained Peripheral Vascular Modulation

This tissue-level effect manifests as peripheral vasodilation (artery widening), which causes a reduction in the Total Systemic Vascular Resistance (SVR), a primary determinant of arterial pressure. The drug's molecular structure, characterized by high lipophilicity, enables it to partition and accumulate within the cell membrane. This reservoir formation results in a slow, sustained release, maintaining the capability for calcium channel blockade and subsequent modulation of vascular tone across a duration of approximately 24 hours.

How to Use Lercanil

The usage of Lercanil (Lercanidipine hydrochloride) is defined by specific protocols regarding how the oral film-coated tablet is administered for the long-term management of high blood pressure. The regimen is built around a once-daily frequency and a mandatory timing requirement relative to food intake.

Official Administration Guidelines

Feature	Instruction
Route	Oral route (film-coated tablet).
Dosing Schedule	Starting dose is 10 mg once daily. The maintenance dose may be increased to a maximum of 20 mg once daily.
Timing Relative to Meals	Must be taken at least 15 minutes before any meal, preferably in the morning.
Preparation	Swallow the tablet whole with a sufficient amount of water.
Missed Dose	If a dose is forgotten, omit the missed dose and take the next dose at the usual scheduled time. Do not take a double dose.

Procedural Structure and Constraints

The official protocol dictates that dose adjustment (titration) from 10 mg to 20 mg must be gradual, as the full effect of the change may not be observed for approximately two weeks. The medicine is not recommended for use in children and adolescents under 18 years of age due to lack of established data. Furthermore, Lercanil must not be taken with grapefruit or grapefruit juice, and consumption of alcohol should be avoided due to the potential for interaction with the drug's effects. The protocol also establishes that use is not recommended in cases of severe kidney or liver impairment.

Research evidence / Overview of Studies for Lercanil

Evidence for Use in Essential Hypertension (Monotherapy)

The primary clinical research for Lercanil involves short-term Randomized Controlled Trials (RCTs). These studies were primarily conducted in adult populations with mild to moderate high blood pressure, and they typically compared Lercanil to either an inactive placebo or to other standard blood pressure treatments.

The main focus of these trials was monitored through the measurement of blood pressure readings in a seated position, specifically recording changes in both Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP). Research also included monitoring blood pressure over a full 24-hour cycle using Ambulatory Blood Pressure Monitoring (ABPM) to explore the patterns of effect over a 24-hour cycle. Studies report how blood pressure parameters evolved in the observed populations during the defined short-term time intervals, such as 4 to 12 weeks.

Evidence in Combination Therapy

Research has also explored Lercanil's use as an add-on therapy for individuals whose blood pressure remained high despite treatment with a single medication. These studies often used factorial-design RCTs to evaluate fixed-dose combinations of Lercanil with other agents, most notably Enalapril (an ACE inhibitor) or Valsartan (an ARB).

These trials research examined whether the combination of different classes of antihypertensive drugs resulted in observed blood pressure changes that differed from the patterns seen with the individual components used alone. Research describes patterns related to blood pressure management when combining agents in cases where single-agent therapy was previously used.

Areas of Research Uncertainty and Gaps

While short-term evidence for blood pressure parameters has been evaluated through RCTs, long-term effects are not fully established regarding major cardiovascular outcomes or mortality. Studies of this drug's impact on hard outcomes (such as stroke or heart attack) over multiple years are often retrospective or observational, meaning comparative evidence is lacking from dedicated, prospective, multi-year RCTs common to older antihypertensive drug classes. Additionally, data for certain groups remain insufficient, especially for those with severe kidney or liver impairment, and for children, as these populations are typically excluded from initial trials. Research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. DailyMed: Lercanidipine hydrochloride tablet
2. Public Assessment Report Lercanidipine hydrochloride

Common questions about Lercanil (FAQ)

Q: Is Lercanil used for something other than blood pressure?

According to the official regulatory documents, Lercanil (lercanidipine hydrochloride) is indicated and approved solely for the treatment of mild to moderate essential hypertension, which is high blood pressure. It is not listed for any other medical uses in the product information.

Q: What is the difference between Lercanil and other common blood pressure pills?

Lercanil belongs to a class of medicines known as calcium channel blockers. Official documents define it as a third-generation dihydropyridine calcium channel blocker. This classification describes its specific action, which is primarily focused on relaxing the walls of blood vessels (vasodilation) to lower the resistance to blood flow and thereby reduce blood pressure.

Q: How quickly should Lercanil start working after I begin taking it?

The official product information indicates that the full therapeutic effect, meaning the maximal blood pressure reduction, may not be achieved immediately. It can take approximately two weeks after starting the drug or changing the dosage before the full effect is apparent.

Q: Is Lercanil safe to use for older adults?

Official prescribing information generally states that a dose adjustment is not typically required for older adults. However, the regulatory guidance states that special care may be needed when treatment is commenced in this population.

Q: What should I do if I experience dizziness after taking Lercanil?

Dizziness is listed as an uncommon side effect of Lercanil. Official product information contains a warning that the presence of dizziness, fatigue, or drowsiness may impair the ability to drive or operate machinery.

Q: Are there any long-term health risks associated with Lercanil use?

Lercanil is classified as a medicine intended for long-term treatment. Lercanil is not classified as an addictive or habit-forming substance. While short-term effects on blood pressure have been studied, official research overviews state that the long-term impact on major cardiovascular events, such as heart attack or stroke, is not fully established.

Q: What makes Lercanil different from Amlodipine?

Lercanidipine is characterized as a 'third-generation' calcium channel blocker. This substance is described in regulatory texts as having high selectivity for the peripheral vascular system (the blood vessels) and a prolonged duration of action.

Q: What is 'peripheral edema' and is it a concern with Lercanil?

Peripheral oedema is a term for swelling, most commonly seen in the ankles or feet, and it is a known effect of many medicines that relax blood vessels. Official documents list peripheral oedema as a common side effect of Lercanil, meaning it may affect up to 1 in 10 people.

Q: What symptoms should prompt someone to seek immediate assistance while on Lercanil?

Regulatory documents describe certain rare but serious side effects that may require immediate medical evaluation. These include signs of an allergic reaction (such as swelling of the face, lips, tongue, or throat), fainting (syncope), or an increase in the frequency, duration, or severity of existing chest pain (angina pectoris).

Q: Does Lercanil interact with common over-the-counter pain relievers?

The official Summary of Product Characteristics (SmPC) does not specifically list common non-prescription pain relievers. However, official regulatory texts note that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the blood pressure-lowering effect of Lercanil.

Q: Does Lercanil cause weight gain or weight loss?

Weight changes (either weight gain or weight loss) are not reported or listed as a known or common adverse reaction in the official regulatory documents for Lercanil.

Q: Can Lercanil affect my ability to drive or operate machinery?

Regulatory information states that Lercanil has negligible influence on the ability to drive or operate machinery. However, regulatory information contains a specific warning that the presence of dizziness, fatigue, or drowsiness may impair the ability to drive or operate machinery, and the presence of these effects requires careful consideration before operating vehicles or heavy equipment.

Q: What is the risk of stopping Lercanil suddenly?

According to the official patient information, stopping treatment suddenly may cause your blood pressure to increase again. The official patient information indicates that treatment should only be stopped under the supervision and direction of a healthcare professional.

Q: Does Lercanil affect blood sugar levels?

Clinical data referenced in regulatory overviews indicate that Lercanil is not typically associated with negative effects on glucose metabolism or blood sugar levels, which is often considered in the context of coexisting conditions.

Q: Is Lercanil habit-forming or addictive?

Lercanil is not classified in regulatory documents as an addictive or habit-forming substance. It is a medicine used for the long-term control of high blood pressure.

Q: Does Lercanil affect sleep?

Sleepiness (somnolence) is listed in official documents as a rare side effect, meaning it may affect up to 1 in 1,000 people. General sleep disturbances are not classified as a common adverse reaction.

Q: What is the term 'essential hypertension' commonly described as?

'Essential hypertension' is the medical term used to describe high blood pressure that does not have an identifiable, specific, underlying medical cause. It is also frequently referred to as primary hypertension.

Q: Does Lercanil require routine blood tests?

Official documents note that changes in liver function, typically detected by blood tests, are a reported side effect of unknown frequency. This information exists as a safety constraint.

Q: Can Lercanil interact with herbal supplements?

Lercanil is processed in the body by a specific enzyme called CYP3A4. Herbal supplements that are known to interfere with (inhibit) this enzyme, such as St. John’s Wort, may affect the concentration of Lercanil in the body. Regulatory guidance requires that patients inform their healthcare provider about all medicines and supplements being used due to the potential for interactions.

Q: Are drug package inserts for Lercanil available online?

Yes, the official patient information leaflets (PILs) and the comprehensive regulatory document (Summary of Product Characteristics or SmPC) for Lercanil are typically made publicly available on the websites of government drug regulatory bodies, such as the MHRA and EMA.

Q: Is Lercanil commonly prescribed globally?

The active substance in Lercanil, Lercanidipine, is approved and marketed under various brand names in a wide range of countries across multiple continents, including Europe and Asia.

Q: Is there a maximum time Lercanil can be used for?

Lercanil is classified as a medicine intended for the long-term management of high blood pressure, and official regulatory texts do not specify a maximum duration of use.

Lercanil (lercanidipine hydrochloride) must be stored and handled according to specific conditions documented in official regulatory labeling to maintain product stability and effectiveness.

Official Storage Requirements

Condition	Requirement
Temperature	Do not store above 25 C.
Protection	Store in the original package to protect the tablets from light and moisture.
Stability	Shelf life is typically 2 or 3 years, dependent upon adherence to the specified storage environment.

Disposal Instructions

Unused or expired Lercanil must not be disposed of with household waste or via wastewater. Any unused medicinal product or waste material must be returned or disposed of strictly in accordance with local regulatory requirements.